CSIRO’s Biomedical Manufacturing team has partnered with the Malaysia Genome and Vaccine Institute (MGVI-NIBM) to build MGVI’s capability to manufacture vaccines, including a Leptospirosis vaccine.
CSIRO support is provided through in-person train‑the‑trainer programs – covering technology readiness and manufacturability assessment – and quality assessments and backstopping observation of MGVI staff.
Currently, Malaysia imports 100% of its vaccines. In line with Malaysia’s National Vaccine Development Roadmap, MGVI is building a facility to conduct pilot-scale vaccine manufacturing and the MVGP project is building MGVI’s capability to manufacture vaccines at this facility. Following successful completion of the project, Malaysia will be able to independently assess, develop, and scale vaccine manufacturing in response to future health threats.
MVGP is also partnering with Malaysia’s Ministry of Science, Technology and Innovation and Ministry of Health.
